logo
Plus   Neg
Share
Email

Nissan Motor Demotes Former Ghosn Aide Hari Nada

Nissan Motor Co. demoted a former Carlos Ghosn aide, Hari Nada, after board of directors had sought removal of the senior vice president overseeing legal matters.

The company said that it has appointed Hari Nada, who is currently senior vice president, as senior advisor overseeing special projects. He will continue to report to Yasuhiro Yamauchi, representative executive officer, acting president and chief executive officer.

Nissan said even though it has found no evidence of inappropriate involvement by Nada in the internal investigation into executive misconduct led by former Chairman Carlos Ghosn and others, the change is aimed to avoid undue suspicion and to enable him to focus on important tasks for the company, such as forthcoming legal action.

The company also said Hitoshi Kawaguchi, currently executive officer, executive vice president and Chief Sustainability Officer overseeing Global External and Government Affairs, Global Communications, Corporate Services, Environment/CSR, IP Promotion, and the Corporate Management Office, will also oversee the Corporate Advisory Office, the Legal Department, Intellectual Property and the Chief Security Office.
Kawaguchi will continue to report to Yasuhiro Yamauchi.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk, chief executive of electric car maker Tesla, said its own battery cells, which are under development now, will not reach high-volume production until 2022. This delay can affect the Cybertruck, Semi, and Roadster programs. He also said the company intends to increase battery cell purchases from partners Panasonic, LG & CATL, and possibly other partners. U.S. Court grants Tiffany's motion to expedite lawsuit against LVMH Moët Hennessy-Louis Vuitton. However, the court has not agreed to Tiffany request for trial before November 24. Biotech company Illumina agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. GRAIL focuses on multi-cancer early detection from blood. It is in the process of developing the technology and providing clinical data required to launch the Galleri multi-cancer screening test.
RELATED NEWS
Follow RTT